We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+13.58%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$17B
AUM Growth
+$1.79B
Cap. Flow
-$229M
Cap. Flow %
-1.35%
Top 10 Hldgs %
33.75%
Holding
1,490
New
144
Increased
706
Reduced
317
Closed
73

Top Buys

Rank Stock Value
1
O icon
Realty Income
O
+$448M
2
AMT icon
American Tower
AMT
+$132M
3
HIW icon
Highwoods Properties
HIW
+$92.2M
4
WELL icon
Welltower
WELL
+$79.2M
5
PLD icon
Prologis
PLD
+$71.1M

Top Sells

Rank Stock Value
1
VER
VEREIT, Inc.
VER
+$434M
2
CONE
CyrusOne Inc Common Stock
CONE
+$386M
3
WY icon
Weyerhaeuser
WY
+$118M
4
HR icon
Healthcare Realty
HR
+$68.6M
5
VTR icon
Ventas
VTR
+$64.7M

Sector Composition

Rank Sector Weight
1 Real Estate 60.4%
2 Technology 9.49%
3 Consumer Discretionary 4.17%
4 Communication Services 4.01%
5 Financials 3.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
1326
Rigel Pharmaceuticals
RIGL
$712M
$1K ﹤0.01%
37
– –
RLMD icon
1327
Relmada Therapeutics
RLMD
$549M
$1K ﹤0.01%
31
– –
RLYB icon
1328
Rallybio
RLYB
$85.8M
$1K ﹤0.01%
+12
New +$1.4K
RNAC icon
1329
Cartesian Therapeutics
RNAC
$225M
$1K ﹤0.01%
7
– –
RPID icon
1330
Rapid Micro Biosystems
RPID
$103M
$1K ﹤0.01%
+101
New +$1.58K
SABS icon
1331
SAB Biotherapeutics
SABS
$264M
$1K ﹤0.01%
+13
New +$1.22K
SIGA icon
1332
SIGA Technologies
SIGA
$240M
$1K ﹤0.01%
172
– –
SMMT icon
1333
Summit Therapeutics
SMMT
$10B
$1K ﹤0.01%
334
– –
SNAP icon
1334
PUT
Snap
SNAP
$8.02B
$1K ﹤0.01%
1,085
– –
STTK icon
1335
Shattuck Labs
STTK
$651M
$1K ﹤0.01%
+123
New +$1.69K
TSHA icon
1336
Taysha Gene Therapies
TSHA
$1.57B
$1K ﹤0.01%
+112
New +$1.69K
VOR icon
1337
Vor Biopharma
VOR
$1.08B
$1K ﹤0.01%
+5
New +$1.44K
VSTM icon
1338
Verastem
VSTM
$547M
$1K ﹤0.01%
27
– –
PSTX
1339
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1K ﹤0.01%
116
– –
GTHX
1340
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1K ﹤0.01%
145
– –
ALPN
1341
DELISTED
Alpine Immune Sciences Inc
ALPN
$1K ﹤0.01%
+85
New +$1.05K
MRNS
1342
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1K ﹤0.01%
58
– –
CBAY
1343
DELISTED
Cymabay Therapeutics
CBAY
$1K ﹤0.01%
152
– –
CYT
1344
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$1K ﹤0.01%
+103
New +$1.57K
ICPT
1345
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1K ﹤0.01%
62
– –
EVLO
1346
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$1K ﹤0.01%
+8
New +$1.35K
TCRR
1347
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$1K ﹤0.01%
131
– –
JNCE
1348
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1K ﹤0.01%
75
– –
PRVB
1349
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$1K ﹤0.01%
106
– –
TCDA
1350
DELISTED
Tricida, Inc. Common Stock
TCDA
$1K ﹤0.01%
110
– –
52 53
54
55 56

Similar funds

SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Daiwa Securities Group's Q4 2021 Portfolio in Review

As of Q4 2021, Daiwa Securities Group held 1,490 positions worth $17B, up 12% from $15.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Daiwa Securities Group's Q4 2021 filing shows 144 new, 706 increased, 317 reduced and 73 closed positions. Its largest new stake was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M. The largest sale was VEREIT, Inc., an estimated $434M.

By sector, the portfolio is most concentrated in Real Estate at 60% of assets, up from 56% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Daiwa Securities Group's largest Q4 2021 buy was State Street SPDR Portfolio S&P 500 High Dividend ETF: 333,500 shares worth $14M.
  • Daiwa Securities Group added most to Realty Income in Q4 2021, an estimated $448M increase.
  • Daiwa Securities Group's biggest Q4 2021 reduction was CyrusOne Inc Common Stock, cutting an estimated $386M.
  • Daiwa Securities Group fully exited VEREIT, Inc. in Q4 2021, selling an estimated $434M.
  • Daiwa Securities Group's ten largest holdings make up 34% of its $17B portfolio in Q4 2021.
  • Daiwa Securities Group opened 144 new positions and closed 73 in Q4 2021.
  • Daiwa Securities Group's portfolio value rose 12% quarter-over-quarter to $17B.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.